Company: Cytophage Technologies
Job title: CEO & CSO
Dr. Steven Theriault is a synthetic biologist with 20 years research and entrepreneurial experience in generating biological solutions for biological problems. Early in his career, he was a member of the team that created the reverse genetic systems critical to the development of the Canadian Ebola vaccine as well as many novel and innovative diagnostic tools to aid in the fight against Ebola. As Chief of the Applied Research Program at the Canadian Science Centre for Human and Animal Health, Dr. Theriault worked extensively at the global level on issues related to the efficacy of microbicides in outbreak zones and containment laboratories.
Recently, Dr. Theriault research interests have turned to combating antimicrobial resistance with synthetic bacteriophages. Dr. Theriault’s company, Cytophage Technologies Inc., unlocks the potential of nature’s elegant and harmless antibacterial solution – phages. Cytophage’s template technology replaces the lengthy discover-in-nature process and bacterial resistance common to natural phages with tailor-made, highly effective, synthetic phages. Cytophage has been recognised internationally as an innovative and potentially disruptive technology.
Dr. Theriault’s goal is to enable phages to become mainstream in treating human and animal bacteria-related infections and contaminations, thereby reducing needless suffering and averting the WHO-predicted crisis from antibiotic resistant infections.
Using Bacteriophages to Prevent Disease in a Large Scale Agricultural Setting 10:40 am
day: Pre-Conference Focus Day